anti-CCL25 HuMab (JYANT technologies)

N/A

Report date: 2025/03/14 16:44:59

Base Information

Drug Nameanti-CCL25 HuMab (JYANT technologies)
Drug Alias NameCCL25 HuMAB
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHormone-Resistant Prostate Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesJyant Technologies
China Registration ClassN/A

Develop Information

Active CompaniesJyant Technologies
Inactive CompaniesN/A
Active IndicationsHormone-Resistant Prostate Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A